Abstract
Altering the human epigenome with gene-editing technology in attempt to treat a variety of diseases and conditions seems scientifically feasible. We explore some of the ethical and regulatory issues related to the clinical translation of human epigenetic editing arguing that such approaches should be considered akin to somatic therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 1652-1655 |
Number of pages | 4 |
Journal | Stem Cell Reports |
Volume | 16 |
Issue number | 7 |
DOIs | |
State | Published - Jul 13 2021 |
ASJC Scopus subject areas
- Biochemistry
- Genetics
- Developmental Biology
- Cell Biology